Makary Signals Some Interest In US FDA Staff Cuts, Fighting Patent Thickets

 
• By Sarah Karlin-Smith

The FDA Commissioner nominee also commented on trial diversity, the role of public comment and expedited biosimilar reviews during his Senate confirmation hearing.

Close up of FDA headquarters building with FDA sign.
FDA Commissioner nominee Martin Makary said he would assess agency personnel and would be "surgical" with any reductions. (Tada Images/Shutterstock)

More from US FDA

More from R&D